Susquehanna International Group’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-63,400
| Closed | -$203K | – | 12569 |
|
|
2024
Q4 | $203K | Buy |
+63,400
| New | +$215K | ﹤0.01% | 10688 |
|
|
2024
Q3 | – | Sell |
-34,200
| Closed | -$73.5K | – | 12088 |
|
|
2024
Q2 | $73.5K | Sell |
34,200
-57,500
| -63% | -$102K | ﹤0.01% | 11219 |
|
|
2024
Q1 | $188K | Buy |
91,700
+40,000
| +77% | +$79.8K | ﹤0.01% | 10662 |
|
|
2023
Q4 | $118K | Buy |
+51,700
| New | +$113K | ﹤0.01% | 11194 |
|
|
2023
Q3 | – | Sell |
-27,700
| Closed | -$68.4K | – | 12100 |
|
|
2023
Q2 | $68.4K | Sell |
27,700
-27,000
| -49% | -$73.8K | ﹤0.01% | 11196 |
|
|
2023
Q1 | $123K | Buy |
+54,700
| New | +$275K | ﹤0.01% | 11104 |
|
|
2022
Q4 | – | Sell |
-2,280
| Closed | -$24K | – | 12527 |
|
|
2022
Q3 | $24K | Sell |
2,280
-1,360
| -37% | -$16.2K | ﹤0.01% | 12526 |
|
|
2022
Q2 | $37K | Sell |
3,640
-1,650
| -31% | -$21.6K | ﹤0.01% | 12126 |
|
|
2022
Q1 | $94K | Buy |
+5,290
| New | +$114K | ﹤0.01% | 11955 |
|
|
2021
Q4 | – | Sell |
-10,750
| Closed | -$355K | – | 13168 |
|
|
2021
Q3 | $355K | Buy |
10,750
+2,410
| +29% | +$71.2K | ﹤0.01% | 10211 |
|
|
2021
Q2 | $246K | Buy |
+8,340
| New | +$231K | ﹤0.01% | 11173 |
|
Susquehanna International Group's CKPT Position: Q2 2025 in Review
Susquehanna International Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 251,213 shares — an estimated $1.01M sold.
Susquehanna International Group first reported a position in CKPT in Q2 2018 and held it in 22 quarters. The position peaked at $2.63M in Q4 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Susquehanna International Group reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 251,213 Checkpoint Therapeutics shares in Q2 2025, an estimated $1.01M.
- Susquehanna International Group first reported a position in Checkpoint Therapeutics in Q2 2018 and held it in 22 quarters.
- Susquehanna International Group's Checkpoint Therapeutics position peaked at $2.63M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.